New Paradigm Would Open More Avenues To Obesity Drug Approval
Executive Summary
Assessments of obesity drugs should look at their effects in patients grouped by health status and FDA should expand the universe of secondary endpoints available to assess benefits, a group of stakeholders says.
You may also be interested in...
Breakthrough Status May Not Be So Groundbreaking, Recent Reviews Indicate
A look at some of FDA’s novel drug approvals analyzed in Pharmaceutical Approvals Monthly’s 2012 series of drug review profiles suggests that the agency has already ushered through several approvals that could be models for the new “breakthrough” designation created by the FDA Safety and Innovation Act.
Breakthrough Status May Not Be So Groundbreaking, Recent Reviews Indicate
A look at some of FDA’s novel drug approvals analyzed in Pharmaceutical Approvals Monthly’s 2012 series of drug review profiles suggests that the agency has already ushered through several approvals that could be models for the new “breakthrough” designation created by the FDA Safety and Innovation Act.
Judging Obesity Drugs: Can Patient-Focused Statistics Bring Simplicity, Clarity?
The odds ratio would be a simpler way to look at an obesity drug’s success in promoting 5% weight loss than the current three-step process, FDA’s statistical reviewer said in her assessment of Belviq’s efficacy.